Video content above is prompted by the following:
- Biosimilars have been shown to reduce costs for patients and the healthcare system in general. Given that, why do you think the uptake of biosimilars is still relatively low?
- How can the uptake of biosimilars into health systems be improved?
- Interchangeability can be employed by pharmacists to switch a reference product with a biosimilar. What are your best practices for employing this in your practice?
- What has your experience been like switching from adalimumab reference product to biosimilars?
- How can switching from adalimumab reference product to biosimilars be improved in the future?
